U.S. Markets closed

Exelixis, Inc. (EXEL)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
18.98+0.14 (+0.74%)
At close: 4:00PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close18.84
Open18.81
Bid19.00 x 800
Ask19.19 x 1300
Day's Range18.81 - 19.16
52 Week Range13.67 - 27.80
Volume1,332,279
Avg. Volume2,145,412
Market Cap5.888B
Beta (5Y Monthly)1.21
PE Ratio (TTM)39.62
EPS (TTM)0.48
Earnings DateFeb 23, 2021 - Mar 01, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est30.85
  • Exelixis In-Licenses Iconic Therapeutics’ Tissue Factor-Targeting Antibody-Drug Conjugate Ahead of Planned Investigational New Drug Application
    Business Wire

    Exelixis In-Licenses Iconic Therapeutics’ Tissue Factor-Targeting Antibody-Drug Conjugate Ahead of Planned Investigational New Drug Application

    Exelixis, Inc. (Nasdaq: EXEL), Iconic Therapeutics, Inc. (Iconic) and Zymeworks Inc. (NYSE:ZYME) today announced that Exelixis has exercised its exclusive option for Iconic’s lead oncology antibody-drug conjugate (ADC) program under the companies’ May 2019 agreement. As a result, Exelixis now has responsibility for the future clinical development, commercialization, and manufacturing of the Tissue Factor (TF)-targeting ADC now known as XB002 (formerly ICON-2). A rationally designed next-generation ADC, XB002 comprises a Tissue Factor-targeting antibody with Zymeworks’ proprietary ZymeLink™ linker-payload, creating the potential for an improved therapeutic index and favorable safety profile as compared to earlier-generation, TF-targeting ADCs. Exelixis plans to file an Investigational New Drug application (IND) with the U.S. Food and Drug Administration (FDA) for XB002 in the near-term and, pending the FDA’s acceptance of the IND, initiate a phase 1 clinical trial of XB002 in early 2021.

  • Exelixis Announces Partner Takeda Receives Approval in Japan for CABOMETYX® (cabozantinib) for the Treatment of Unresectable Hepatocellular Carcinoma That Has Progressed After Prior Systemic Therapy
    Business Wire

    Exelixis Announces Partner Takeda Receives Approval in Japan for CABOMETYX® (cabozantinib) for the Treatment of Unresectable Hepatocellular Carcinoma That Has Progressed After Prior Systemic Therapy

    Exelixis, Inc. (NASDAQ: EXEL) today announced that Takeda Pharmaceutical Company Limited (Takeda), its partner responsible for the clinical development and commercialization of CABOMETYX® (cabozantinib) in Japan, received approval from the Japanese Ministry of Health, Labor and Welfare to manufacture and market CABOMETYX as a treatment for patients with unresectable hepatocellular carcinoma (HCC) that has progressed after prior systemic therapy.

  • Got $50? 4 Smart Stocks to Buy Into Right Now
    Motley Fool

    Got $50? 4 Smart Stocks to Buy Into Right Now

    This year, the investing community has been taken on a roller-coaster ride that involved the quickest bear market decline of at least 30% in history, the most ferocious rebound from a bear market bottom on record, and multiple single-session nominal point swings in the Dow Jones Industrial Average and S&P 500 that broke records. It's not often that you'll find growth and value wrapped up in one stock, but that's exactly what investors are going to get if they choose to take their $50 and purchase shares of cancer-drug developer Exelixis (NASDAQ: EXEL). Exelixis' primary growth driver is a Food and Drug Administration-approved drug known as Cabometyx.